OverviewSuggest Edit

Abbott is a healthcare company specializing in diagnostics, medical devices, nutritionals, and branded generic medicines. It has expertise in glucose monitoring, blood and plasma screening, adult nutrition, pediatric nutrition, remote heart failure monitoring, point of care testing. The company offers a variety of chronic pain devices and heart pumps (LVADs).
TypePublic
Founded1888
HQLake Bluff, IL, US
Websiteabbott.com
Employee Ratings3.9
Overall CultureC+

Latest Updates

Employees (est.) (Dec 2019)107,000(+4%)
Job Openings4,724
Revenue (FY, 2020)$34.6 B(+9%)
Share Price (May 2021)$118.9
Cybersecurity ratingBMore

Key People/Management at Abbott

Miles D. White

Miles D. White

Executive Chairman of the Board
Robert B. Ford

Robert B. Ford

President and Chief Executive Officer
Hubert L. Allen

Hubert L. Allen

Executive Vice President, General Counsel and Secretary
Lisa D. Earnhardt

Lisa D. Earnhardt

Executive Vice President, Medical Devices
John F. Ginascol

John F. Ginascol

Executive Vice President, Core Diagnostics
Andrew H. Lane

Andrew H. Lane

Executive Vice President, Established Pharmaceuticals
Show more

Abbott Office Locations

Abbott has offices in Lake Bluff, Alameda, Austin, Des Plaines and in 125 other locations
Lake Bluff, IL, US (HQ)
100 Abbott Park Rd
Alameda, CA, US
1420 Harbor Bay Pkwy
Austin, TX, US
6300 Bee Cave Rd building 2, suite 100
Des Plaines, IL, US
1300 E Touhy Ave
Hollywood, FL, US
4000 Hollywood Blvd #333
Lake Forest, IL, US
100 S Saunders Rd
Show all (148)

Abbott Financials and Metrics

Abbott Revenue

Embed Graph
View revenue for all periods
Abbott's revenue was reported to be $34.61 b in FY, 2020
USD

Revenue (Q1, 2021)

10.5b

Gross profit (Q1, 2021)

6.1b

Gross profit margin (Q1, 2021), %

57.9%

Net income (Q1, 2021)

1.8b

EBIT (Q1, 2021)

2.1b

Market capitalization (7-May-2021)

210.7b

Closing stock price (7-May-2021)

118.9

Cash (31-Mar-2021)

8.1b

EV

221.1b
Abbott's current market capitalization is $210.7 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

27.4b30.6b31.9b34.6b

Revenue growth, %

31%12%4%

Cost of goods sold

12.3b12.7b13.2b15.0b

Gross profit

15.1b17.9b18.7b19.6b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

7.4b7.8b7.7b7.5b8.0b8.1b7.7b7.3b8.9b10.5b

Cost of goods sold

3.1b3.3b3.2b3.2b3.3b3.4b3.3b3.3b4.0b4.4b

Gross profit

4.3b4.5b4.5b4.4b4.7b4.7b4.4b4.1b4.9b6.1b

Gross profit Margin, %

58%58%59%58%59%58%58%55%55%58%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

9.4b3.8b3.9b6.8b

Accounts Receivable

5.2b5.2b5.4b6.4b

Inventories

3.6b3.8b4.3b5.0b

Current Assets

20.1b14.6b15.7b20.4b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

3.9b3.1b7.4b3.0b3.1b4.1b3.4b4.8b4.5b8.1b

Accounts Receivable

5.4b5.2b5.3b5.3b5.5b5.5b5.3b5.1b5.6b6.1b

Inventories

3.8b3.7b3.8b4.1b4.4b4.4b4.6b5.2b5.2b5.4b

Current Assets

15.0b14.1b18.2b14.4b15.2b16.1b15.5b17.2b17.4b21.8b
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

477.0m2.4b3.7b4.5b

Depreciation and Amortization

3.0b3.3b3.0b3.3b

Inventories

249.0m(514.0m)(593.0m)(493.0m)

Accounts Payable

615.0m747.0m1.8b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

418.0m1.2b1.7b672.0m1.7b2.6b564.0m1.1b2.3b1.8b

Depreciation and Amortization

852.0m1.7b2.5b753.0m1.5b2.3b828.0m1.7b2.5b934.0m

Inventories

(171.0m)(336.0m)(450.0m)(286.0m)(540.0m)(730.0m)(437.0m)(987.0m)(838.0m)(537.0m)

Cash From Operating Activities

1.1b2.4b4.5b712.0m1.8b3.7b715.0m2.0b4.1b2.6b
USDFY, 2017

Revenue/Employee

276.7k

Debt/Equity

0.9 x

Debt/Assets

0.4 x

Financial Leverage

2.5 x
Show all financial metrics

Abbott Operating Metrics

FY, 2017FY, 2018FY, 2019

Products

1.5 k1.5 k1.5 k

New Product Launches

2525

Manufacturing Sites

1009492

Manufacturing Sites (Cardiovascular and Neuromodulation Products)

252527
Show all operating metrics

Abbott Acquisitions / Subsidiaries

Company NameDateDeal Size
Cephea Valve TechnologiesJanuary 16, 2019
AlereAugust 14, 2017$5.3 b
St. Jude MedicalApril 28, 2016$25 b
Kalila MedicalApril 06, 2016
Tendyne Holdings, Inc.July 31, 2015$250 m
VeropharmDecember 12, 2014$305 m
Topera, Inc.October 29, 2014$250 m
CFR PharmaceuticalsMay 15, 2014$2.9 b
IDEV Technologies, Inc.July 15, 2013$310 m
OptiMedicaJuly 15, 2013$400 m
Show more

Abbott Revenue Breakdown

Embed Graph

Abbott revenue breakdown by business segment: 42.2% from Medical Devices, 16.6% from Diagnostics, 15.5% from Established Pharmaceuticals, 25.5% from Nutritionals and 0.2% from Other

Abbott revenue breakdown by geographic segment: 36.2% from All Other Countries, 7.4% from China, 5.5% from Germany, 35.7% from United States and 15.3% from Other

Abbott Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Abbott Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Abbott Online and Social Media Presence

Embed Graph

Abbott Company Culture

  • Overall Culture

    C+

    67/100

  • CEO Rating

    A-

    74/100

  • Compensation

    B-

    67/100

  • Diversity

    C+

    67/100

Learn more on Comparably

Abbott Blogs

United and Abbott Partner to Make Return to U.S. “Worry Free” for International Travelers with Home-Testing Kits

- Newly issued guidance from the U.S. Centers for Disease Control and Prevention now accepts rapid, self-administered testing option that meet its criteria

Abbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial

- A new, first-of-its-kind study known as TAP-CHF leverages expertise across Abbott's cardiovascular portfolio to optimize treatment for patients suffering from both AFib and heart failure

Abbott’s New Coronary Imaging Platform Powered by Artificial Intelligence Launches in Europe

- New imaging platform merges optical coherence tomography (OCT) with the power of automation using artificial intelligence (AI)

World's Fastest Marathoner Eliud Kipchoge Uses Abbott's Libre Sense at NN Mission Marathon Qualifier Race for the Olympic Games

- Abbott, Eliud Kipchoge and the NN Running Team collaborate in a partnership to track glucose levels during training and marathons

Abbott Receives CE Mark Approval for Next-Generation TriClip™ Device, Offering New Innovations for Tricuspid Heart Valve Repair

- New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve

Abbott's XIENCE™ Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding Risk Patients

- New shorter duration of dual anti-platelet therapy (DAPT) post XIENCE stent implant provides physicians with additional options to treat patients at high risk of bleeding
Show more

Abbott Frequently Asked Questions

  • When was Abbott founded?

    Abbott was founded in 1888.

  • Who are Abbott key executives?

    Abbott's key executives are Miles D. White, Robert B. Ford and Hubert L. Allen.

  • How many employees does Abbott have?

    Abbott has 107,000 employees.

  • What is Abbott revenue?

    Latest Abbott annual revenue is $34.6 b.

  • What is Abbott revenue per employee?

    Latest Abbott revenue per employee is $323.4 k.

  • Who are Abbott competitors?

    Competitors of Abbott include Otricath, Baxter International and Quest Diagnostics.

  • Where is Abbott headquarters?

    Abbott headquarters is located at 100 Abbott Park Rd, Lake Bluff.

  • Where are Abbott offices?

    Abbott has offices in Lake Bluff, Alameda, Austin, Des Plaines and in 125 other locations.

  • How many offices does Abbott have?

    Abbott has 148 offices.